Impact of NR3C1 rs41423247 (BclI) Polymorphism on Disease Severity in Alopecia Areata

Alopecia areata is an autoimmune, non-scarring hair loss disorder with multifactorial pathogenesis. The glucocorticoid receptor gene (NR3C1) plays an essential role in immune regulation and inflammatory response. The rs41423247 polymorphism (BclI) may influence glucocorticoid sensitivity and disease activity. This study aims to investigate the association between NR3C1 rs41423247 polymorphism and susceptibility to alopecia areata and to evaluate its correlation with disease severity using the Severity of Alopecia Tool (SALT) score.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alopecia Areata(AA) Alopecia Alopecia Areata Hair Diseases Hypotrichosis Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Benha University

Banhā, Qalyubia Governorate, 13511, Egypt

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(Cases):

Clinically diagnosed alopecia areata
Age ≥ 18 years
Both sexes
Willingness to participate and provide informed consent

Inclusion criteria

(Controls):

Apparently healthy individuals
No history of autoimmune disease
Age- and sex-matched to cases
Provided informed consent

Exclusion criteria

Presence of other autoimmune or inflammatory diseases
Current systemic immunosuppressive therapy
Pregnancy or lactation
Refusal to participate

Treatment and study plan

Primary outcomes

Distribution of NR3C1 rs41423247 Genotypes and Alleles

Time frame: Baseline

Comparison of genotype and allele frequencies of NR3C1 rs41423247 polymorphism between alopecia areata patients and healthy controls.

Secondary outcomes

Association Between NR3C1 rs41423247 Polymorphism and Disease Severity

Time frame: Baseline

Correlation between NR3C1 rs41423247 genotypes and Severity of Alopecia Tool (SALT) score in patients with alopecia areata.

Sponsors and collaborators

Lead sponsor

Benha University

Other

Registry information

Official study title

Assessment of Glucocorticoid Receptor Gene Polymorphism in Alopecia Areata

Acronym: NR3C1 and AA

Important dates

Study start: 2023
Primary completion: 2024
Study completion: 2024
First posted: Mar 6, 2026
Registry last updated: Mar 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed